Improved outcome in South African children of mixed ethnicity treated for all
Date
2006
Authors
Dippenaar A.
Wessels G.
Hesseling P.B.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
□ A historical cohort study with an analytical component was conducted to determine whether risk-appropriate chemotherapy can improve survival in children of mixed ethnicity with ALL. Eighty-one coloured children treated for ALL in South Africa were divided into 2 groups: group A (n = 39), treated prior to 1992, and group B (n = 42), treated after 1992. A comparison was made of survival, treatment complications, and supportive measures. The two groups were comparable. The mean nadirs of the white cell count (p < .01), platelet count (p = .01), and hemoglobin value (p < .01) were significantly lower in group B. The survival rate of 37% in group A improved to 66% in group B (p = .025). The results show that a risk-adapted regimen increased survival in children of mixed ethnicity in the Western Cape, despite increased hematological toxicity and episodes of febrile neutropenia. Copyright © Taylor & Francis Group, LLC.
Description
Keywords
amikacin, antineoplastic agent, asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, granulocyte colony stimulating factor, mercaptopurine, methotrexate, piperacillin, prednisone, tioguanine, vancomycin, vincristine, article, blood transfusion, bone marrow toxicity, brain radiation, cancer chemotherapy, cancer survival, child, childhood leukemia, clinical protocol, erythrocyte transfusion, ethnic group, febrile neutropenia, female, human, major clinical study, male, South Africa, thrombocyte transfusion, treatment outcome, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Cohort Studies, Ethnic Groups, Female, Hemoglobins, Humans, Leukemia, Lymphocytic, Acute, L1, Leukocyte Count, Male, Neutropenia, Platelet Count, South Africa, Survival Rate, Time Factors, Treatment Outcome
Citation
Pediatric Hematology and Oncology
23
4
23
4